Bayer eyes deals in 'attractive' Indonesian market; Canadians pay double for generics;

 @FiercePharma: When docs go electronic, they report more side effects. Article | Follow @FiercePharma

> Bayer's drug unit is interested in acquisitions and partnerships in Indonesia, says Suchitra Kataria, head of business development and in-licensing for Asia Pacific. Report

> Canadians pay almost twice as much as Americans for generic medicines because government drug plans distort retail prices and prevent manufacturer discounts from being passed on to consumers, claims a new Fraser Intitute report. Fraser Institute release | Report

> Johnson & Johnson will be hoping to take some of the focus off the manufacturing problems that have led to 11 product recalls, multiple government probes and public embarrassment when it reports its Q3 results before the stock market opens Tuesday. News

> Germany's Stada aims to tap into the bond market for its future financial needs to become more independent of banks, CFO Helmut Kraft told a German newspaper. Report

> New long-term data for Novartis' once-yearly osteoporosis jab Aclasta/Reclast have cemented its safety and efficacy profile, showing that the drug preserves bone mass and slashes the risk of new spine fractures. Novartis release | Article

> The FDA and Pan American Health Organization are collaborating to develop an information hub for medical products and regulatory processes in the Americas. Report

> Dr. Reddy's Laboratories says it will soon start selling a generic version of Takeda Pharmaceutical's ulcer drug Prevacid in the U.S. market. Story

> Questcor Pharmaceuticals says the FDA approved its Acthar gel to treat seizures in infants, sending its shares up as much as 10 percent. Report

Biotech News

 @FierceBiotech: Myriad Genetics' shares rise on takeover talk. Report | Follow @FierceBiotech

> Eli Lilly will axe 130 staffers as it shutters Singapore R&D center. Article 

> Sanofi will attend Harvard in hunt for new blockbusters. News 

> Genmab will look to U.S. partner to push PhIII zalutumumab work. Item

> Patient death mars promising MS results in PhII ocrelizumab trial. Article 

Biotech IT News

> J&J teams with Microsoft for biologics. News 

> Oracle's CDA 2.0 enhances transactional data analytics. Item 

> Clients re-up with growing DATATRAK. Story 

> Cmed boasts iPad version of Timaeus CTMS. Article

> Instem to use IPO funds to augment drug safety offering. Report

> Galderma selects Medidata Rave, mentoring service. Story

And Finally... Scientists have identified the eight human papillomavirus (HPV) types responsible for more than 90 percent of cervical cancer cases worldwide and say they should be the targets for the next generation of vaccines. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.